Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis

Echocardiography

Volumn 22, Issue 6, 2005, Pages 473-478

  Arat Özkan, Alev ^a,c   Kaya, Ayşem ^b   Yiǧit, Zerrin ^a   Balci, Huriye ^b   Ökçün, Bariş ^a   Yazicioǧlu, Nuran ^a   Küçükoǧlu, Serdar ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Brain natriuretic peptide; Echocardiography; Functional capacity; Mitral stenosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HUMAN; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN DETERMINATION; SINUS RHYTHM;

CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 21644472066     PISSN: 07422822     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8175.2005.04085.x     Document Type: Article

References (32)

1. Levin ER, Gardner DG, Samson WK: Mechanism of disease-natriuretic peptides. N Engl J Med 1998;339:321-328.
2. Cheung BMY, Kumana CR: Natriuretic peptides-relevance in cardiovascular disease. JAMA 1998;280:1983-1984.
3. Richards AM, Nicholls MG, Yandle TG, et al: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin-new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998;97:1921-1929.
4. Omland T, Aakvaag A, Bonarjee W, et al: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-1969.
5. Hall C, Rouleau JL, Moye L, et al: N-terminal proatrial natriuretic factor. An independent predictor of long term prognosis after myocardial infarction. Circulation 1994;89:1934-1942.
6. McDonagh TA, Cunningham AD, Morrison CD, et al: Left ventricular dysfunction, natriuretic peptides and mortality in an urban population. Heart 2001;86(1):21-26.
7. McDonagh TA, Robb SD, Murdoch DR, et al: Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
8. Lerman A, Gibbons RJ, Rodeheffer RJ, et al: Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left ventricular dysfunction. Lancet 1993;341:1105-1109.
9. Tsutamoto T, Wada A, Maeda K, et al: Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 1999;20:1799-1807.
10. Brookes CI, Kemp MW, Hooper J, et al: Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis 1997;6:608-612.
11. Sutton TM, Stewart RAH, Gerber IL, et al: Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003;12:2280-2287.
12. Talwar S, Downie PF, Squire IB, et al: Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail 2001;3:15-19.
13. Nakamura M, Kawata Y, Yoshida H, et al: Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J 1992;124(5):1283-1288.
14. Yoshimura M, Yasue H, Okumura K, et al: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993;87(2):464-469.
15. Troughton RW, Frampton CM, Yandle TG, et al: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
16. Hunt PJ, Yandle TG, Nicholls MG, et al: The aminoterminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 1995;214:1175-1183.
17. Talwar S, Siebenhofer A, Williams B, et al: Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart 2000;83(3):278-282.
18. Talwar S, Squire IB, Davies JE, et al: Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur Heart J 1999;20:1736-1744.
19. Schiller NB, Shah PM, Crawford M, et al: Recommendations for quantitation of the left ventricle by two dimensional echocardiography: American Society of Echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
20. Remme WJ, Swedberg K: Role of natriuretic peptides in the diagnosis of heart failure. Eur J Cardiol 2001;22:1535.
21. Niinuma H, Nakamura M, Hiramori K: Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998:90:89-94.
22. Tourneau TL, De Groote P, Millaire A, et al: Effect of mitral valve surgery on exercise capacity, ventricular ejection fraction and neurohormonal activation in patients with severe mitral regurgitation. J Am Coll Cardiol 2000;36(7):2263-2269.
23. Fukuda N, Shinohara H, Sakabe K, et al: Plasma levels of brain natriuretic peptide in various forms of obstruction to the left ventricular outflow tract. J Heart Valve Dis 2003;12(3):333-340.
24. Mukoyama M, Nakao K, Hosoda K, et al: Brain natriuretic peptide as a novel cardiac hormone in humans. Biochem Biophys Res Commun 1989;158:360-368.
25. Nakao K, Mukoyama M, Hosoda K, et al: Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol 1991;69:1500-1506.
26. Yasue H, Yoshimura M, Sumida H, et al: Localisation and mechanism of secretion of B-type natriuretic peptide in comparison with those of a-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
27. Ohta Y, Shimada T, Yoshitomi H, et al: Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol 2001;17:415-420.
28. Tharaux PL, Dussaule JC, Hubert-Brierre J, et al: Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. Clin Sci 1994;87(6):671-677.
29. Matsumoto A, Hirata Y, Momomura S, et al: Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J 1995;129(1):139-145.
30. Nagaya N, Nishikimi T, Okano Y, et al: Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-208.
31. Lee SC, Stevens TL, Sandberg SM, et al: The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002;8(3):149-154.
32. Watanabe M, Murakami M, Furukawa H, et al: Is measurement of brain plasma natriuretic peptide levels a useful test to detect for surgical timing of valve disease?. Int J Cardiol 2004;96:21-24.